Edwards Lifesciences Corp (EW) as of March 31, 2026 presents a strongly positive liquidation posture relative to most medtech peers, though the intangible-heavy balance sheet and large unresolved tax contingencies are the primary risk factors under a wind-down scenario. Total assets of $13.3B are dominated by goodwill ($1.8B), other intangibles ($1.2B), and a deferred tax asset ($1.1B), all of which receive zero recovery under liquidation assumptions. Stripping those out and applying standard haircuts, recoverable asset value is approximately: cash and equivalents $2.4B at 100%, short-term investments $1.2B at ~98%, accounts receivable $0.8B at ~92%, inventory $1.1B at ~60% ($670M), and PP&E $1.8B at ~60% ($1.1B). Gross haircut recoverable asset pool is roughly $6.8B to $7.0B before contingent tax liabilities. Against total liabilities of $3.0B (face value), of which $599M is the 2018 senior notes due June 2028 and $555M is long-term unrecognized tax positions, residual equity recovery exists in the base case. However, the critical liquidation risk is the IRS transfer pricing dispute: the filing discloses $792M in gross uncertain tax position liabilities, with $400M net impact on effective tax rate if settled adversely. Post-Q1 2026, the company received two draft NOPAs for 2018-2020 proposing incremental taxable income adjustments of up to $625M, $531M, and $684M for three years, potentially generating hundreds of millions in additional tax exposure beyond what is accrued. Management states no additional amounts have been recorded beyond existing UTB accruals. These contingent tax liabilities are not separately carried as a balance sheet liability beyond the $555M noncurrent UTB line, and the full range of downside (which could exceed $500M in unaccrued exposure) is not recoverable from the $57M litigation reserve. Separately, a $124M VIE impairment charge was taken in Q1 2026, eliminating that asset from the recoverable pool. The February 2026 Autus acquisition adds $129M in goodwill/intangibles with up to $333M in future contingent milestone payments that would constitute unrecorded obligations. Operating cash flow deteriorated sharply in Q1 2026 to $44M from $280M in Q1 2025, driven by working capital headwinds and $347M reduction in accounts payable and accrued liabilities, which is atypical and warrants monitoring for structural vs. timing explanations. The filing discusses the $380M IRS deposits (converted to advance payments) as a potential refund receivable in judicial proceedings; this $400M income tax receivable is carried on the balance sheet and would recover at par if refunds are obtained. MFFAIS CLV of $358M understates the liquidation picture materially; that figure likely reflects only the most conservative (cash/liquid) pool. OLV of $2.3B is a more plausible floor, consistent with the recoverable tangible asset base after netting face-value liabilities, though the IRS tail risk could compress this by $300-500M in an adverse scenario.
▼ Community Notes